Market Cap
US$18.8b
Last Updated
2019/09/16 23:40 UTC
Data Sources
Company Financials +
Executive Summary
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases.
Snowflake
Fundamentals
Reasonable growth potential with proven track record.
Similar Companies
Share Price & News
How has ResMed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-3.3%
NYSE:RMD
0.8%
US Medical Equipment
1.1%
US Market
1 Year Return
15.9%
NYSE:RMD
9.6%
US Medical Equipment
2.1%
US Market
RMD outperformed the Medical Equipment industry which returned 9.1% over the past year.
RMD outperformed the Market in United States of America which returned 2% over the past year.
Share holder returns
| RMD | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.3% | 0.8% | 1.1% |
| 30 Day | -2.8% | 0.2% | 3.7% |
| 90 Day | 9.3% | 2.7% | 2.3% |
| 1 Year | 17.5%15.9% | 10.5%9.6% | 4.4%2.1% |
| 3 Year | 115.3%105.1% | 69.5%64.3% | 47.0%37.4% |
| 5 Year | 183.6%159.3% | 132.5%105.9% | 61.6%43.8% |
Price Volatility Vs. Market
How volatile is ResMed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Do Directors Own ResMed Inc. (NYSE:RMD) Shares?2 months ago | Simply Wall St
Is ResMed (NYSE:RMD) A Risky Investment?2 months ago | Simply Wall St
Does ResMed Inc.'s (NYSE:RMD) P/E Ratio Signal A Buying Opportunity?Valuation
Is ResMed undervalued based on future cash flows and its price relative to the stock market?
46.23x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
ResMed's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
ResMed's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
ResMed is overvalued based on earnings compared to the US Medical Equipment industry average.
ResMed is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
ResMed is poor value based on expected growth next year.
Price Based on Value of Assets
ResMed is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is ResMed expected to perform in the next 1 to 3 years based on estimates from 15 analysts?
15.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
ResMed's revenue is expected to grow by 8.3% yearly, however this is not considered high growth (20% yearly).
ResMed's earnings are expected to grow by 15% yearly, however this is not considered high growth (20% yearly).
ResMed's revenue growth is expected to exceed the United States of America market average.
ResMed's earnings growth is expected to exceed the United States of America market average.
ResMed's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
ResMed is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
Next Steps
Past Performance
How has ResMed performed over the past 5 years?
2.0%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
ResMed's year on year earnings growth rate has been positive over the past 5 years.
ResMed's 1-year earnings growth exceeds its 5-year average (28.2% vs 2%)
ResMed's earnings growth has not exceeded the US Medical Equipment industry average in the past year (28.2% vs 28.9%).
Return on Equity
ResMed has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
ResMed used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
Return on Capital Employed
ResMed has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is ResMed's financial position?
Financial Position Analysis
ResMed is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
ResMed's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
ResMed's level of debt (61.3%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has increased over the past 5 years (17.2% vs 61.3% today).
Debt is well covered by operating cash flow (36.1%, greater than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 18.8x coverage).
Balance Sheet
Low level of unsold assets.
Debt is not covered by short term assets, assets are 0.9x debt.
Next Steps
Dividend
What is ResMed's current dividend yield, its reliability and sustainability?
1.30%
Expected Dividend Yield
Dividend Yield and Payments Analysis
ResMed's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.45%).
ResMed's dividend is below the markets top 25% of dividend payers in United States of America (3.67%).
Whilst dividend payments have been stable, ResMed has been paying a dividend for less than 10 years.
Dividend payments have increased, but ResMed only paid a dividend in the past 7 years.
Current Payout to Shareholders
Dividends paid are covered by earnings (1.9x coverage).
Future Payout to Shareholders
Dividends after 3 years are expected to be well covered by earnings (2.8x coverage).
Next Steps
Management
What is the CEO of ResMed's salary, the management and board of directors tenure and is there insider trading?
6.5yrs
Average management tenure
CEO
Mick Farrell (47yo)
6.5yrs
Tenure
US$9,082,204
Compensation
Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA has been the Chief Executive Officer of ResMed Inc. since March 1, 2013. Mr. Farrell served as President of Americas Operations at ResMed Inc. since ...
CEO Compensation Analysis
Mick's remuneration is about average for companies of similar size in United States of America.
Mick's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
6.5yrs
Average Tenure
56yo
Average Age
The average tenure for the ResMed management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
5.8yrs
Average Tenure
61yo
Average Age
The tenure for the ResMed board of directors is about average.
Insider Trading
ResMed individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Lead Director Lead Independent Director |
| Shares | 4,429 |
| Max Price | US$136.34 |
| Entity | Individual |
| Shares | 12,306 |
| Max Price | US$127.06 |
| Entity | Individual |
| Shares | 16,739 |
| Max Price | US$101.50 |
| Entity | Individual |
| Shares | 1,800 |
| Max Price | US$111.56 |
| Entity | Individual |
| Role | Senior Key Executive President of Sleep Business |
| Shares | 5,893 |
| Max Price | US$105.52 |
| Entity | Company |
| Shares | 3,300 |
| Max Price | US$104.49 |
| Entity | Individual |
| Role | President President & COO |
| Shares | 984 |
| Max Price | US$101.44 |
Ownership Breakdown
Management Team
David Pendarvis (60yo)
Chief Administrative Officer
- Tenure: 8.3yrs
- Compensation: US$2.72m
Connie Bienfait
Director of Investor Relations
- Tenure: 0yrs
Brett Sandercock (52yo)
Chief Financial Officer
- Tenure: 13.7yrs
- Compensation: US$2.86m
Rob Douglas (59yo)
President & COO
- Tenure: 6.5yrs
- Compensation: US$6.25m
Mick Farrell (47yo)
CEO & Director
- Tenure: 6.5yrs
- Compensation: US$9.08m
Geoff Neilson
Senior Vice President of Global Supplier Alliance
- Tenure: 4.8yrs
Jim Hollingshead (56yo)
President of Sleep Business
- Tenure: 8.3yrs
- Compensation: US$3.17m
Bobby Ghoshal
Chief Technology Officer
- Tenure: 1.4yrs
Amy Wakeham
Vice President of Investor Relations & Corporate Communications
- Tenure: 0yrs
Nupur Bhushan
Chief People Officer
- Tenure: 2.2yrs
Board Members
Rich Sulpizio (69yo)
Director
- Tenure: 14.1yrs
- Compensation: US$330.02k
Jack Wareham (78yo)
Director
- Tenure: 14.7yrs
- Compensation: US$321.75k
Peter Farrell (77yo)
Founder & Non-Executive Chairman
- Tenure: 5.7yrs
- Compensation: US$768.92k
Ron Taylor (71yo)
Lead Independent Director
- Tenure: 6.2yrs
- Compensation: US$345.02k
Jan De Witte (55yo)
Non-Executive Director
- Tenure: 0.3yrs
Harjit Gill (54yo)
Director
- Tenure: 0.8yrs
Mick Farrell (47yo)
CEO & Director
- Tenure: 6.5yrs
- Compensation: US$9.08m
Carol Burt (61yo)
Director
- Tenure: 5.8yrs
- Compensation: US$323.27k
Karen Drexler (59yo)
Director
- Tenure: 1.8yrs
- Compensation: US$290.64k
Company Information
ResMed Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: ResMed Inc.
- Ticker: RMD
- Exchange: NYSE
- Founded: 1989
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$18.779b
- Shares outstanding: 143.67m
- Website: https://www.resmed.com
Number of Employees
Location
- ResMed Inc.
- 9001 Spectrum Center Boulevard
- San Diego
- California
- 92123
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RMD | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jun 1995 |
| RME | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 1995 |
| 0KW4 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jun 1995 |
| RMD | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jun 1995 |
| RMD * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jun 1995 |
| RMD | ASX (Australian Securities Exchange) | CDI COM USD0.004 (10CDI/1SHS) | AU | AUD | Nov 1999 | |
| RSMD.F | OTCPK (Pink Sheets LLC) | CDI COM USD0.004 (10CDI/1SHS) | US | USD | Nov 1999 | |
| RMEA | DB (Deutsche Boerse AG) | CDI COM USD0.004 (10CDI/1SHS) | DE | EUR | Nov 1999 | |
| RMD | CHIA (Chi-X Australia) | CDI COM USD0.004 (10CDI/1SHS) | AU | AUD | Nov 1999 |
Biography
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/16 23:40 |
| End of Day Share Price | 2019/09/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.